Literature DB >> 33125611

MicroRNA-20a-5p suppresses tumor angiogenesis of non-small cell lung cancer through RRM2-mediated PI3K/Akt signaling pathway.

Junlei Han1, Jianping Hu2, Fang Sun1, Hongzhi Bian1, Bingxiang Tang1, Xiang Fang1.   

Abstract

The current therapeutic strategies for non-small cell lung cancer (NSCLC) are limited and unsatisfactory. MicroRNAs (miRNAs) participate in tumor angiogenesis in NSCLC. The aim of this study was to investigate the role of miR-20a-5p (miR-20a) in human NSCLC metastasis. In the current study, bioinformatics analysis and RT-PCR were performed to examine the expression level of miR-20a in tissues of NSCLC patients and NSCLC cell lines, respectively. Western blot was performed to test the protein levels. Cell proliferation, migration and angiogenesis capacity were tested by 5-ethynyl-29-deoxyuridine (EdU) assay, transwell assay and tube formation assay, respectively. Dual-luciferase reporter assay (DLR) was used to confirm the interaction between miR-20a and paired ribonucleotide reductase regulatory subunit M2 (RRM2). We found that the expression of RRM2 was upregulated, while the expression of miR-20a was downregulated in cancer tissues compared with adjacent tissues in NSCLC patients. We also detected the expression level of RRM2 and miR-20a in NSCLC cell lines, showing A549 cell line exhibited the lowest expression level of miR-20a and highest expression level of RRM2. Overexpressed miR-20a not only dramatically suppressed NSCLC cells proliferation, endothelial cells migration and tube formation in vitro, but also inhibited tumor growth and angiogenesis in vivo. It was demonstrated that miR-20a suppressed NSCLC growth by inhibiting RRM2-mediated PI3K/Akt signaling pathway. These findings indicate that the novel identified miR-20a could function as a tumor suppressor in NSCLC through modulating the RRM2-mediated PI3K/Akt axis, and it could be a valid molecular target for NSCLC treatment.

Entities:  

Keywords:  Angiogenesis; MicroRNA-20a; NSCLC; Ribonucleotide reductase regulatory subunit M2

Mesh:

Substances:

Year:  2020        PMID: 33125611     DOI: 10.1007/s11010-020-03936-y

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  29 in total

Review 1.  MicroRNAs: something important between the genes.

Authors:  Allison C Mallory; Hervé Vaucheret
Journal:  Curr Opin Plant Biol       Date:  2004-04       Impact factor: 7.834

2.  MiR-1260b promotes the migration and invasion in non-small cell lung cancer via targeting PTPRK.

Authors:  Limin Xu; Xuting Xu; Huilian Huang; Zhihong Ma; Shuangmei Zhang; Pingping Niu; Yingrong Chen; Jinliang Ping; Ping Lu; Caihua Yu; Lishan Min; Jing Chen; Licheng Dai; Shunli Dong
Journal:  Pathol Res Pract       Date:  2018-02-14       Impact factor: 3.250

Review 3.  Current Diagnosis and Management of Small-Cell Lung Cancer.

Authors:  Shuhang Wang; Stefan Zimmermann; Kaushal Parikh; Aaron S Mansfield; Alex A Adjei
Journal:  Mayo Clin Proc       Date:  2019-08       Impact factor: 7.616

Review 4.  Targeting miRNAs by polyphenols: Novel therapeutic strategy for cancer.

Authors:  Kasi Pandima Devi; Tamilselvam Rajavel; Maria Daglia; Seyed Fazel Nabavi; Anupam Bishayee; Seyed Mohammad Nabavi
Journal:  Semin Cancer Biol       Date:  2017-02-07       Impact factor: 15.707

Review 5.  MicroRNA and cancer--a brief overview.

Authors:  Mario Acunzo; Giulia Romano; Dorothee Wernicke; Carlo M Croce
Journal:  Adv Biol Regul       Date:  2014-09-28

6.  MicroRNA-29c inhibits proliferation and promotes apoptosis in non-small cell lung cancer cells by targeting VEGFA.

Authors:  Shijuan Zhan; Chunfeng Wang; Fangqing Yin
Journal:  Mol Med Rep       Date:  2018-03-05       Impact factor: 2.952

7.  Epidemiology of lung cancer and lung cancer screening programs in China and the United States.

Authors:  Dawei Yang; Yang Liu; Chunxue Bai; Xiandong Wang; Charles A Powell
Journal:  Cancer Lett       Date:  2019-10-07       Impact factor: 8.679

Review 8.  MicroRNA therapeutics: towards a new era for the management of cancer and other diseases.

Authors:  Rajesha Rupaimoole; Frank J Slack
Journal:  Nat Rev Drug Discov       Date:  2017-02-17       Impact factor: 84.694

9.  miRNA-221 promotes cutaneous squamous cell carcinoma progression by targeting PTEN.

Authors:  Zhen-Hua Gong; Feng Zhou; Chao Shi; Tie Xiang; Chang-Kai Zhou; Qian-Qian Wang; Ya-Su Jiang; Sheng-Feng Gao
Journal:  Cell Mol Biol Lett       Date:  2019-03-08       Impact factor: 5.787

10.  A Strong Decrease in TIMP3 Expression Mediated by the Presence of miR-17 and 20a Enables Extracellular Matrix Remodeling in the NSCLC Lesion Surroundings.

Authors:  Karolina H Czarnecka; Bartosz Szmyd; Magda Barańska; Marcin Kaszkowiak; Jacek Kordiak; Adam Antczak; Dorota Pastuszak-Lewandoska; Ewa Brzeziańska-Lasota
Journal:  Front Oncol       Date:  2019-12-13       Impact factor: 6.244

View more
  11 in total

1.  Cancer-associated fibroblast-derived exosomal microRNA-20a suppresses the PTEN/PI3K-AKT pathway to promote the progression and chemoresistance of non-small cell lung cancer.

Authors:  Lin Shi; Weiliang Zhu; Yuanyuan Huang; Lin Zhuo; Siyun Wang; Shaobing Chen; Bei Zhang; Bin Ke
Journal:  Clin Transl Med       Date:  2022-07

2.  [miR-20a-5p inhibits proliferation of lung cancer A549 cells by down-regulating HOXB13].

Authors:  H Liu; J Wang; J Shen; X Wu; Y Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-04-20

3.  Efficacy and Safety of PD-1/PD-L1 Inhibitor Chemotherapy Combined with Lung Cancer Fang No. 1 in Relapsed and Refractory SCLC: A Retrospective Observational Study.

Authors:  Lihua Wang; Xiaoxia Lei; Xin Wang
Journal:  Comput Math Methods Med       Date:  2022-05-09       Impact factor: 2.809

Review 4.  Regulatory mechanism of miR-20a-5p expression in Cancer.

Authors:  Wei Huang; Xiaoyue Wu; Shuaixi Xiang; Mingxin Qiao; Xiao Cen; Xuefeng Pan; Xinqi Huang; Zhihe Zhao
Journal:  Cell Death Discov       Date:  2022-05-16

5.  circRNA LDLRAD3 Enhances the Malignant Behaviors of NSCLC Cells via the miR-20a-5p-SLC7A5 Axis Activating the mTORC1 Signaling Pathway.

Authors:  Yu Li; Guangle Qin; Jinyun Du; Peng Yue; Yanling Zhang; Na Hou
Journal:  J Healthc Eng       Date:  2022-01-06       Impact factor: 2.682

6.  Long Noncoding RNA LINC01703 Exacerbates the Malignant Properties of Non-Small Cell Lung Cancer by Upregulating MACC1 in a MicroRNA-605-3p-Mediated Manner.

Authors:  Ziyi Wang; Xinyu Zhang; Xuedong Zhang; Xuedong Jiang; Wenya Li
Journal:  Oncol Res       Date:  2021-09-07       Impact factor: 5.574

Review 7.  Novel Angiogenic Regulators and Anti-Angiogenesis Drugs Targeting Angiogenesis Signaling Pathways: Perspectives for Targeting Angiogenesis in Lung Cancer.

Authors:  Yingying Li; Mengmeng Lin; Shiyuan Wang; Bo Cao; Chunyu Li; Guohui Li
Journal:  Front Oncol       Date:  2022-03-16       Impact factor: 6.244

8.  microRNA-20b-5p overexpression combing Pembrolizumab potentiates cancer cells to radiation therapy via repressing programmed death-ligand 1.

Authors:  Kexin Jiang; Huawei Zou
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

9.  LncRNA HOTAIR facilitates proliferation and represses apoptosis of retinoblastoma cells through the miR-20b-5p/RRM2/PI3K/AKT axis.

Authors:  Ke Fu; Ke Zhang; Xiaoyu Zhang
Journal:  Orphanet J Rare Dis       Date:  2022-03-05       Impact factor: 4.123

10.  The identification of hub biomarkers and pathways in lung cancer and prognostic evaluation.

Authors:  Yi Yin; Dong Li; Muqun He; Jianfeng Wang
Journal:  Transl Cancer Res       Date:  2022-08       Impact factor: 0.496

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.